News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,027 Results
Type
Article (2427)
Company Profile (39)
Press Release (35561)
Section
Business (14112)
Career Advice (77)
Deals (2076)
Drug Delivery (8)
Drug Development (4097)
Employer Resources (10)
FDA (429)
Job Trends (761)
News (20124)
Policy (1051)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3467)
ALS (4)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (14)
Approvals (432)
Artificial intelligence (9)
Autoimmune disease (2)
Automation (1)
Bankruptcy (11)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (17)
Cancer (125)
Cardiovascular disease (4)
Career advice (64)
Career pathing (1)
CAR-T (14)
Cell therapy (41)
Cervical cancer (2)
Clinical research (3165)
Collaboration (87)
Compensation (43)
COVID-19 (180)
CRISPR (7)
C-suite (25)
Cystic fibrosis (2)
Data (96)
Denatured (3)
Depression (3)
Diabetes (9)
Diagnostics (461)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4219)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (5993)
Executive appointments (84)
FDA (470)
Featured Employer (3)
Funding (74)
Gene editing (14)
Gene therapy (15)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (14)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (986)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (18)
MASH (3)
Medical device (306)
Medtech (306)
Mergers & acquisitions (1150)
Metabolic disorders (31)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (86)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (325)
Now hiring (4)
Obesity (15)
Opinion (15)
Ovarian cancer (10)
Pain (8)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (1)
Patents (19)
Patient recruitment (2)
Peanut (1)
People (5621)
Pharmaceutical (5)
Phase I (1368)
Phase II (1586)
Phase III (843)
Pipeline (62)
Podcasts (4)
Policy (10)
Postmarket research (30)
Preclinical (587)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (20)
Real estate (419)
Recruiting (5)
Regulatory (799)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (24)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (330)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (488)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1593)
Vaccines (28)
Venture capitalists (7)
Webinars (2)
Weight loss (11)
Women's health (1)
Worklife (1)
Date
Today (2)
Last 7 days (44)
Last 30 days (200)
Last 365 days (2536)
2025 (585)
2024 (2610)
2023 (2859)
2022 (3751)
2021 (4048)
2020 (3471)
2019 (2062)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1858)
Australia (298)
California (756)
Canada (128)
China (36)
Colorado (19)
Connecticut (10)
Delaware (3)
Europe (3801)
Florida (43)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (30)
Japan (7)
Kansas (12)
Maryland (24)
Massachusetts (277)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (2)
New Jersey (65)
New York (43)
North Carolina (87)
Northern California (325)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (43)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (330)
Tennessee (2)
Texas (62)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (43)
Wisconsin (6)
38,027 Results for "aptose biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
March 17, 2025
·
3 min read
Press Releases
Aptose Announces Reverse Share Split
February 19, 2025
·
5 min read
Press Releases
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 22, 2024
·
5 min read
Press Releases
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
February 12, 2025
·
7 min read
Press Releases
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
February 14, 2025
·
5 min read
Biotech Beach
Aptose Announces Results from Annual and Special Meeting of Shareholders - June 18, 2024
Aptose Biosciences Inc. announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024.
June 18, 2024
·
5 min read
Business
Aptose Reports Results for the First Quarter 2024
Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
14 min read
Drug Development
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Biosciences Inc. announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.
June 14, 2024
·
8 min read
Press Releases
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
January 10, 2025
·
5 min read
Press Releases
Aptose Reports Results for the Third Quarter 2024
November 11, 2024
·
13 min read
1 of 3,803
Next
